Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MrMugsyon Nov 10, 2023 8:14pm
264 Views
Post# 35729706

RE:RE:RE:RE:RE:Need for Additional Financing

RE:RE:RE:RE:RE:Need for Additional FinancingFirst - let's assume that the judge decides in Nuance's favour.
When will they decide?
Does that mean that ATE has to pay the following day?  No.
How much time would ATE have to make the payment?
What if ATE requests to pay it back in installments?
What other delay tactics does ATE have that can be used?
What does a challenge look like and what if ATE doesn't pay for a year - 2 years - etc.
We know you can always find ways to delay.

Then - forget about how the market reacts.  Who cares how the market reacts? That doesn't matter to P2.

Delay ... get through P2 and negotiate partnerships.

-------------------------------

Now ... how likely is Nuance to win?  That's something we can't answer because we don't know what was argued on either side ... in the Singapore Court.  We don't know what facts were shared with the Judge and we don't know what is deemed credible.

Therefore ... back to what we do know.  You know we had a data room set up.  Think about what that means and how that plays a role.  Think about Dan's comment ... without merit (or whatever he actually said).

Ignore all paperwork that comes your way for a little while.  Don't answer calls, don't go to the door and don't go to the mailbox.  Certainly don't open any long-distance packages.  Provide instruction to your legal team that you are away and wont be returning for a little while.

Then ... focus on P2 ... folowed by partnerships.

That's all my friend.  And that's just putting 10 minutes of thought into it.

If you ask a lawyer - I bet they will have more successful options at their disposal to delay ... delay ... and then delay a little more.


<< Previous
Bullboard Posts
Next >>